Additional file 1: Fig S5), Pulmonary fibrosis (RR 0.39, 95% CI 0.131.16, p = 0.09
A 2023 meta-analysis in The Lancet Diabetes & Endocrinology covering over 60,000 patients across GLP-1 receptor agonist trials found no statistically significant increase in acute pancreatitis risk (OR 1.02
7 Exenatide and PD Exenatide is the first GLP-1 RA that was approved by the FDA
What makes Ipamorelin stand out is its selectivity: it stimulates GH without meaningfully raising cortisol (the stress hormone) or prolactin, which some older, less selective compounds do
About this article Cite this article Wayu, M., Nepal, R.C., Gbomina, A
The class that started with a twice-daily Gila monster peptide is now expanding into oral small molecules and triple agonists and the dosing decision for any individual patient is going to depend more, not less, on how their biology responds